Great science means sharing knowledge and resources to work faster and achieve more.
Academic collaborations are a rich source of creativity and scientific talent. Pooling resources and expertise can help the UK life sciences community to find and develop new medicines and vaccines. It’s what we call our “R&D ecosystem”.
Pfizer contributes to over a hundred research collaborations and strategic alliances across the UK.1 Through these partnerships, we work with scientists, academics and clinicians to deliver world leading scientific research.
We are part of a collaboration that aims to speed up the exome sequencing of 500,000 UK participants.
An early-stage partnering model that fosters collaborative relationships with selected academic institutions in key hubs of scientific excellence.
A collaborative initiative that aims to make a difference to patients with cancer through ‘precision’ medicine.
Our INSPIRE partnerships with NHS research networks are part of Pfizer’s international network of preferred sites for clinical research.
In 2015 we joined ADDoPT, a 4 year £20.4 million collaborative project between government, pharmaceutical companies, SME's and academia.
Between 2014 and 2018, Pfizer collaborated with the UK-based Medical Research Council to make available a ‘virtual library’ of compounds for use by academic researchers in the UK.
Pfizer data on file. March 2021.